All News
Filter News
Found 185 articles
-
ORYZON Reports Results and Corporate Update for Q4 and Year Ended December 31, 2021
2/7/2022
Oryzon Genomics, S.A. today reported financial results for the fourth quarter of 2021 and provided an update on recent developments.
-
Atomwise Strengthens its Management Team, Adds Veteran Biopharma Leader David Thomson, Ph.D. as Chief Scientific Officer and Two Additional Senior Appointments
1/25/2022
Atomwise, a leader in using artificial intelligence (AI) for small molecule drug discovery, announced today the appointment of David Thomson, Ph.D. as Chief Scientific Officer.
-
ORYZON Announces New Senior VP of Clinical Development and Global Medical Affairs, Continuing its Expansion of US Corporate Activities
1/11/2022
Oryzon Genomics, S.A. announced that Dr. Ana Limón has been appointed as Senior Vice President of Clinical Development and Global Medical Affairs.
-
Clinical Catch-Up: January 3-7
1/10/2022
The biopharma industry has started 2022 with plenty of clinical trial news. Here’s a look. -
Biopharma and life sciences companies and organizations provide updates on their businesses and pipelines.
-
ORYZON Announces Approval for Serbian Arm of PORTICO, Vafidemstat’s Phase IIb Trial in Borderline Personality Disorder
1/4/2022
Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), announced today that it has received approval from the Serbian Medicines and Medical Devices Agency (ALIM) for its Clinical Trial Application (IND equivalent) to conduct a Phase IIb clinical trial with vafidemstat in patients with Borderline Personality Disorder (BPD) in Serbia.
-
ORYZON to Hold Multiple Corporate Activities in January 2022
1/3/2022
Oryzon Genomics, S.A. announced that its management will update on corporate progress at several renowned international events in January.
-
Clinical Catch-Up: December 11-17
12/20/2021
It was an enormously busy week with plenty of announcements from the American Society of Hematology meeting and numerous companies working to get the news out ahead of the holidays and year-end. Here’s a look. -
ORYZON at ASH-2021: Iadademstat 36-month ALICE Data Demonstrate Robust Efficacy in Combination with Azacitidine in AML
12/13/2021
Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), today presents new positive efficacy data from its ongoing Phase IIa ALICE trial, investigating iadademstat in combination with azacitidine in elderly or unfit patients with acute myeloid leukemia (AML), at the 63rd American Society of Hematology Annual Conference, ASH-2021.
-
Clinical Catch-Up: November 15-19
11/22/2021
With the last full week before the Thanksgiving week in the U.S., companies had a fair amount of clinical trial news. Here’s a look. -
ORYZON Announces New Global Chief Business Officer and Expansion of US Corporate Activities
11/22/2021
Oryzon Genomics, S.A., a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced that Dr. Saikat Nandi has been appointed as Global Chief Business Officer.
-
ORYZON Enrolls First Patient in EVOLUTION, a Phase IIb Clinical Trial With Vafidemstat in Schizophrenia
11/17/2021
Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), announced today the enrollment of the first patient in the EVOLUTION Phase IIb clinical trial with vafidemstat in patients with schizophrenia, at the Vall d’Hebrón Hospital in Barcelona, Spain.
-
ORYZON Publishes Paper in ACS Pharmacology & Translational Science Supporting Best-in-Class Performance of Iadademstat in Oncology
11/15/2021
Oryzon Genomics, S.A., a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announces the publication of a scientific paper in the peer-reviewed international scientific journal, ACS Pharmacology & Translational Science.
-
ORYZON to Present New Clinical Data and Corporate Updates at International Conferences in November and December
11/9/2021
Oryzon Genomics, S.A. announced today that it will present new clinical data and present company updates at several renowned international conferences in November and December.
-
ORYZON Reports Results and Corporate Update for Quarter Ended September 30, 2021
10/28/2021
Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, today reported financial results for the third quarter of 2021 and provided an update on recent developments.
-
Clinical Catch-Up: October 18-22
10/25/2021
It was yet another busy week for clinical trial news. Here’s a look. -
Biopharma and life sciences companies from across the globe provide updates on their pipelines and business operations.
-
Clinical Catch-Up: October 11-15
10/18/2021
It was yet another busy week for clinical trial announcements. Take a look. -
ORYZON enrolls first patient in the US in PORTICO, a Phase IIb clinical trial with vafidemstat in Borderline Personality Disorder
10/18/2021
Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), announced today the enrollment of the first patient in the US in its Phase IIb clinical trial with vafidemstat, a selective inhibitor of the epigenetic target LSD1, in Borderline Personality Disorder (BPD) patients.
-
Biopharma and life sciences companies from across the globe provide updates on their pipelines and business operations.